Desensitization of 5-HT(1A) autoreceptors by a low chronic fluoxetine dose effect of the concurrent administration of WAY-100635 by Hervás, Ildefonso et al.
 N
 
EUROPSYCHOPHARMACOLOGY
 
 
 
2001
 
–
 
VOL
 
. 
 
24
 
, 
 
NO
 
. 
 
1
 
© 2000 American College of Neuropsychopharmacology
Published by Elsevier Science Inc. 0893-133X/01/$–see front matter
655 Avenue of the Americas, New York, NY 10010  PII S0893-133X(00)00175-5
Desensitization of 5-HT
 
1A
 
 Autoreceptors by a 
Low Chronic Fluoxetine Dose
Effect of the Concurrent Administration
of WAY-100635
 
Ildefonso Hervás, Ph.D., M. Teresa Vilaró, Ph.D., Luz Romero, Ph.D., M. Cecilia Scorza, M.D., 
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Using microdialysis, receptor autoradiography and in situ 
hybridization, we examined the effects of fluoxetine alone or 
with WAY-100635 on: (a) extracellular 5-HT in frontal 
cortex; and (b) density and sensitivity of 5-HT
 
1A
 
 
autoreceptors in rat brain. WAY-100635 (0.3 mg/kg, s.c.) 
doubled the increase in extracellular 5-HT produced by 
fluoxetine (3 mg/kg, i.p.) in frontal cortex. Two-week 
minipump treatments with these daily doses significantly 
raised extracellular 5-HT to 275 
 
6
 
 33% (fluoxetine) and
245 
 
6
 
 10% (fluoxetine plus WAY-100635) of controls. 
Fluoxetine 3 mg/kg·day desensitized dorsal raphe 5-HT
 
1A
 
 
autoreceptors, an effect prevented by the concurrent WAY-
100635 administration. However, WAY-100635 (alone or 
with fluoxetine) did not change 5-HT
 
1A
 
 autoreceptor 
sensitivity. The density of 5-HT
 
1A
 
 receptors and its encoding 
mRNA, was unaffected by these treatments. These results 
suggest that prolonged blockade of 5-HT
 
1A
 
 receptors in vivo 
prevents the autoreceptor desensitization induced by 
fluoxetine but does not result in receptor sensitization. 
 
[Neuropsychopharmacology 24:11–20, 2001]
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Selective serotonin (5-hydroxytryptamine, 5-HT) re-
uptake inhibitors (SSRIs) are extensively used in the
treatment of major depression. The increase in fore-
brain extracellular 5-HT elicited by SSRIs is limited by a
negative feed-back involving raphe autoreceptors (Arti-
gas et al. 1996). The prevention of this inhibitory mech-
anism with 5-HT
 
1A
 
 receptor antagonists augments the
neurochemical and behavioral effects of SSRIs (Gartside
et al. 1995; Artigas et al. 1996; Hashimoto et al. 1997;
Mitchell and Redfern 1997; Grignaschi et al. 1998; Trillat
et al. 1998). At the clinical level, the 
 
b
 
-adrenoceptor/
5-HT
 
1A
 
 receptor antagonist pindolol accelerates the an-
tidepressant effects of SSRIs in open-label and placebo-
controlled trials (Artigas et al. 1994; Blier and Bergeron
1995; Pérez et al. 1997; Zanardi et al. 1997, 1998; Bordet
et al. 1998). However, its effectiveness to potentiate an-
tidepressant response in chronically ill or treatment-
resistant patients is still controversial (Maes et al. 1996,
1999; Berman et al. 1997; Moreno et al. 1997; Pérez et al.
1999). Based on this rationale, selective 5-HT
 
1A
 
 receptor
antagonists (for use with SSRIs; add-on strategy) and
dual action compounds (5-HT reuptake inhibitor 
 
1
 
 5-HT
 
1A
 
antagonist) are being developed for use in the treat-
ment of major depression.
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The prolonged administration of SSRIs has been re-
ported to desensitize raphe 5-HT
 
1A
 
 autoreceptors, as as-
sessed by single unit recordings and brain microdialy-
sis (Blier and de Montigny 1994; Invernizzi et al. 1994;
Arborelius et al. 1995; Le Poul et al. 1995). This reduces
the efficacy of the above negative feedback and in-
creases extracellular 5-HT (Bel and Artigas 1993; Inv-
ernizzi et al. 1994; Rutter et al. 1994; Arborelius et al.
1996). Other studies, however, have failed to observe
such effects even using large doses of SSRIs (Hjorth and
Auerbach 1994a; Auerbach and Hjorth 1995; Bosker et
al. 1995; Invernizzi et al. 1995).
To our knowledge, there are no published reports on
the effects of prolonged treatments with combinations
of SSRIs and 5-HT
 
1A
 
 receptor antagonists on these ex-
perimental paradigms, except in abstract form (Dawson
et al. 1998). As with pindolol, future selective 5-HT
 
1A
 
 re-
ceptor antagonists would be administered for a limited
period of time. Should prolonged blockade of 5-HT
 
1A
 
receptor result in receptor sensitization, the withdrawal
of the antagonist would increase the efficacy of the
above negative feed-back and reduce the ability of the SSRI
to increase extracellular 5-HT, thus increasing the possi-
bility of a clinical relapse. Since this is crucial for the
success of this therapeutic strategy, we examined the ef-
fects of two-week treatments with fluoxetine, WAY-
100635 and their combination on the labeling and sensi-
tivity of 5-HT
 
1A
 
 autoreceptors in rat brain .
 
METHODS
Microdialysis Procedures
 
Male Wistar rats (280–300 g; Iffa-Credo, Lyon, France)
were used. Animal care followed the European Union
regulations (O.J. of E.C. L358/1 18/12/1986). A de-
tailed description of the microdialysis procedures can
be found in Adell and Artigas (1998). Briefly, anesthe-
tized rats (pentobarbital, 60 mg/kg, i.p.) were placed in
a David Kopf (Tujunga, CA) stereotaxic frame. Concen-
tric dialysis probes (4.0 mm long) were implanted in
frontal cortex and secured to the skull with anchor
screws and dental cement. Dialysis membranes were
made from hollow Cuprophan fibers with 252 
 
m
 
m OD,
220 
 
m
 
m ID, and 5000-dalton molecular weight cutoff
(GFE09; Gambro, Lund, Sweden).
The stereotaxic coordinates (in mm; AP 
 
1
 
3.4, DV
 
2
 
6.0, L 
 
2
 
2.5) were taken from bregma and dura mater
according to the rat brain atlas of Paxinos and Watson
(1986). Rats were allowed to recover from anesthesia in
the dialysis cages (cubic, 40 cm each side) and 20–24 h
later the probes were perfused with artificial CSF
(aCSF; composition: NaCl 125 mM, KCl 2.5 mM, MgCl
 
2
 
1.18 mM, and CaCl
 
2
 
 1.26 mM; pH 6.5–7.0) at 0.25 
 
m
 
l/
min. In some experiments, the aCSF was supplemented
with 1 
 
m
 
M of the SSRI citalopram.
Dialysate samples of 5 
 
m
 
l were collected at 20-min in-
tervals into polypropylene microcentrifuge vials. After
an initial 1-h sample of dialysate was discarded, four to
six fractions were collected to obtain basal values before
drug administration. At the end of the experiments, rats
were killed by an overdose of sodium pentobarbital and
the placement of the dialysis probes was checked by
perfusing Fast Green dye and examination of the probe
track after cutting the brain at the appropriate level.
5-HT was analyzed by a modification of a high per-
formance liquid chromatography method previously
described (updated in Adell and Artigas 1998). 5-HT
was separated on a 3 
 
m
 
m ODS 2 column (7.5 cm 
 
3
 
 0.46
cm; Beckman, San Ramon, CA) and detected ampero-
metrically with a Hewlett Packard 1049 detector set at
the potential of 
 
1
 
0.6V. Retention time was 3.5–4 min.
The detection limit for 5-HT was typically 0.5–1 fmol/
sample. Dialysate 5-HT values were calculated by refer-
ence to standard curves run daily.
 
Treatments
 
Four different experiments were conducted. In the first
one, we examined the effects on extracellular 5-HT in
frontal cortex of single doses of fluoxetine (3 mg/kg, i.p.)
plus (20 min later) saline or WAY-100635 [
 
N
 
-(2-(4-(2-
methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridyl)
cyclohexanecarboxamide
 
?
 
3HCl] (RBI, Natick, MA) (0.3
mg/kg, s.c.). A second experiment assessed the effect of
two-week minipump treatments with fluoxetine (3 mg/
kg·day) and fluoxetine plus WAY-100635 (0.3 mg/
kg·day) on the basal extracellular 5-HT concentration. In
this group, microdialysis experiments were conducted on
the 14th day of treatment, with the minipump on board.
In a third experiment, the same treatments (fluoxe-
tine 3 mg/kg·day and fluoxetine 3 mg/kg·day plus
WAY-100635 0.3 mg/kg·day) were given but minipumps
were removed under light anesthesia on day 14th and
microdialysis experiments were conducted two days
later to examine the labeling and sensitivity of 5-HT
 
1A
 
receptors. A complete washout of fluoxetine was ex-
pected at this time, as judged from its complete elimina-
tion in two days from the brain compartment after 21-
day treatments with higher doses (10–30 mg/kg·day)
(Gardier et al. 1993). In these experimental groups, dial-
ysis probes were perfused with an artificial CSF contain-
ing 1 
 
m
 
M citalopram. In this experimental condition, the
systemic administration of SSRIs reduces extracellular
5-HT due to the activation of somatodendritic 5-HT
 
1A
 
autoreceptors (see Discussion). With the same time
schedule (two-week treatment plus two-day washout)
and experimental conditions, a fourth experiment exam-
ined the effect of WAY-100635 (0.3 mg/kg·day) alone on
the sensitivity of raphe 5-HT
 
1A
 
 receptors. Control rats in
all groups received the corresponding vehicle for the
same time periods.
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In chronic experiments, rats were implanted s.c. with
Alzet 2002 minipumps filled to deliver vehicle (water/
dimethyl sulfoxide 50/50%), fluoxetine 3 mg/kg·day
(Eli Lilly and Co., Indianapolis, IN), WAY-100635 0.3
mg/kg·day or fluoxetine plus WAY-100635 for 14 days.
Drugs were dissolved in vehicle. The use of dimethyl
sulfoxide to dissolve fluoxetine was necessary due to
the small volume of minipumps (300 
 
m
 
l). Given the
weight gain of the animals, the doses used correspond
to the 7th day of treatment. After minipump implants,
rats were kept one per cage. After removal, the
minipumps were cut with an incisor blade and checked
that they were empty by careful visual inspection.
 
Autoradiography and 
 
In Situ
 
 Hybridization
 
We assessed the effect of the above minipump treatments
on the labeling of 5-HT
 
1A
 
 receptors using receptor autora-
diography and on the mRNA encoding 5-HT
 
1A
 
 receptors
by 
 
in situ
 
 hybridization. These experiments were per-
formed in rats subjected to a two-week treatment plus a
two-day washout period, after the microdialysis experi-
ments had been completed. The brains were carefully
removed from the skull, frozen on dry ice and kept
at 
 
2
 
20 
 
8
 
C until sample processing. A detailed description
of the autoradiographic and 
 
in situ
 
 hybridization proce-
dures is given in Casanovas et al. (1999a). Brain sections,
14 
 
m
 
m thick, were cut on a microtome-cryostat, thaw-
mounted, and kept at 
 
2
 
20
 
8
 
C until used. [
 
3
 
H]-8-OH-DPAT
(234 Ci/mmol) (Amersham, UK) was used as ligand.
Tissues were preincubated to wash out endogenous
5-HT and exogenously administered drugs that could
potentially interfere with the labeling of 5-HT
 
1A
 
 recep-
tors. Optimal preincubation time was determined in pi-
lot experiments using sections containing the dorsal
raphe nucleus (DR) and the hippocampus (rich in
postsynaptic 5-HT
 
1A
 
 receptors) and found to be 120 min
(a plateau was reached at 90 min). After preincubation,
sections were incubated in the presence of [
 
3
 
H]-8-OH-
DPAT (0.5 nM). Non-specific binding was defined in the
presence of 10 
 
m
 
M 5-HT. Sections were washed and
dried before exposure (14 days, 4
 
8
 
C) to Hyperfilm-
 
3
 
H
(Amersham, UK).
For 
 
in situ
 
 hybridization experiments, an oligonucle-
otide probe complementary to the mRNA coding for
the rat 5-HT
 
1A
 
 receptor (amino acids 407–422) was used
(Pompeiano et al. 1992). The oligonucleotide was 3’
end-labeled with terminal deoxynucleotidyltransferase
(Boehringer Mannheim) and [
 
32
 
P]
 
a
 
-dATP (3000 Ci/
mmol; DuPont New England Nuclear). Tissue sections
were pretreated and hybridized as described (Casano-
vas et al. 1999a). Hybridized sections were exposed to
 
b
 
-max film (Amersham) for 12 days at 
 
2
 
70
 
8
 
C with in-
tensifying screens. Quantitative image analysis was
performed with the MCID computerized image analy-
sis system (St Catharines, Ontario, Canada).
 
Data Treatment
 
Dialysate 5-HT concentrations are expressed as fmol/
fraction and represented in some figures as percentage
of baseline (average of four pre-drug fractions). The sta-
tistical analysis of raw data (in fmol/fraction) was per-
formed using two-way analysis of variance (ANOVA)
for repeated measures with time and pretreatment (ve-
hicle, fluoxetine, WAY-100635, or fluoxetine plus WAY-
100635) as main effects. We analysed the effect of the in-
dependent factor (treatment group), the repeated factor
(time) and the interaction between them. The latter as-
sesses whether the change in 5-HT from pre-drug val-
ues differs between the two treatment groups. Thus, a
significant 
 
p
 
-value of the interaction indicates differ-
ences in the effects of two treatments on extracellular
5-HT. One-way ANOVA for independent data followed
by post-hoc tests was also used. Results are expressed
as mean 
 
6
 
 SEM. Statistical significance has been set at
the 95% confidence level (two-tailed).
 
RESULTS
Acute Treatment with Fluoxetine and Fluoxetine 
 
1
 
 
WAY-100635
 
Rats were treated with fluoxetine 3 mg/kg, i.p. Twenty
minutes later, they received an injection of saline or
WAY-100635 0.3 mg/kg, s.c. Baseline 5-HT values were
1.5 
 
6
 
 0.1 fmol/fraction in the fluoxetine plus saline
group (
 
n
 
 
 
5
 
 6) and 2.1 
 
6
 
 0.4 fmol/fraction in the fluoxe-
tine plus WAY-100635 group (
 
n
 
 
 
5
 
 8). Extracellular 5-HT
in frontal cortex raised to a maximum of 154 
 
6
 
 19% of
baseline in the rats treated with fluoxetine and saline
and to 213 
 
6
 
 10% of baseline in rats treated with fluox-
etine plus WAY-100635. Two-way repeated measures
Figure 1. Effect of the administration of (first arrow) 3 mg/
kg fluoxetine and (second arrow) saline (open circles, n 5 6)
or WAY-100635 0.3 mg/kg (filled circles; n 5 8) on extracellu-
lar 5-HT in frontal cortex. The effect of fluoxetine plus WAY-
100635 was significantly greater than that of fluoxetine alone
(two-way repeated measures ANOVA; see text for details).
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ANOVA indicated a significant effect of the group (F
 
1,12
 
 
 
5
 
7.27, 
 
p
 
 
 
,
 
 .02), time (F
 
12,144
 
 
 
5
 
 9.37, 
 
p
 
 
 
,
 
 .001) and time 
 
3
 
group interaction (F
 
12,144 5 3.43, p , .001) (Figure 1).
Effect of 2-Week Treatments with Fluoxetine and 
Fluoxetine 1 WAY-100635 on Extracellular 5-HT
The baseline extracellular 5-HT (average of four 20-min
fractions) was determined in rats treated with mini-
pumps for two weeks with vehicle, fluoxetine 3 mg/
kg·day, and fluoxetine 3 mg/kg·day plus WAY-100635
0.3 mg/kg·day (no washout) and found to be 2.9 6 0.3
(n 5 7), 8.0 6 1.0 (n 5 8), and 7.1 6 0.3 fmol/fraction
(n 5 7), respectively. One-way ANOVA for independent
measures revealed a significant effect of the group (F2,21 5
17.49, p , .0001) with significant differences between the
fluoxetine and fluoxetine plus WAY-100635 groups vs.
controls (post-hoc Tukey test) (Figure 2).
Desensitization of 5-HT1A Receptors
After a two-day washout, the baseline 5-HT concentra-
tion (in presence of 1 mM citalopram) in rats pretreated
for two weeks with vehicle, fluoxetine 3 mg/kg·day, or
fluoxetine 3 mg/kg·day plus WAY-100635 0.3 mg/
kg·day was 33.5 6 2.0 fmol/fraction (n 5 6), 24.9 6 2.6
fmol/fraction (n 5 7), and 20.3 6 2.6 fmol/fraction (n 5
7), respectively. The 5-HT values in the latter group
were significantly different from controls (Tukey test
post one-way ANOVA).
The administration of 10 mg/kg, i.p. fluoxetine re-
duced extracellular 5-HT to 53% of baseline in control
rats. The analysis by two-way ANOVA of fractions 1–13
(effect of the fluoxetine challenge) in all groups indi-
cated the existence of a significant effect of time (F12,204 5
37.21, p , .001), group (F2,17 5 6.34, p , .009) and time 3
group interaction (F24,204 5 2.58, p , .001). Likewise,
one-way ANOVA of the average 5-HT values during
the period of maximal effect (fractions 8–13) followed
Figure 2. Effect of two-week treatments with vehicle (open
bar; n 5 7), fluoxetine 3 mg/kg·day (filled bar; n 5 8), or fluox-
etine 3 mg/kg·day plus 0.3 mg/kg·day WAY 100635 (cross-
hatched bar; n 5 7) on the basal extracellular 5-HT in frontal
cortex. *p , .05 vs. controls (Tukey test post-ANOVA).
Figure 3. (A) In presence of citalopram in the perfusion fluid, fluoxetine (10 mg/kg i.p., first arrow) significantly reduced extra-
cellular 5-HT in frontal cortex of rats treated with vehicle (Controls; open circles, n 5 6), fluoxetine 3 mg/kg·day (FLX 3; filled
circles, n 5 7), and fluoxetine 3 mg/kg·day plus WAY-100635 0.3 mg/kg·day (FLX 3 1 WAY 0.3; filled triangles, n 5 7)
(significant effect of the time and group 3 time interaction; see text). The reduction in extracellular 5-HT was fully counteracted
by the systemic administration of WAY-100635 (0.3 mg/kg, s.c.; second arrow), indicating the involvement of 5-HT1A autorecep-
tors in this effect. (B) Average reduction (fractions 8–13) of extracellular 5-HT produced by fluoxetine 10 mg/kg in the three
experimental groups (vehicle, open bar; fluoxetine, filled bar; fluoxetine plus WAY-100635, crosshatched bar). *p , .05 vs. con-
trols.
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by Tukey test revealed a significantly lower reduction
of 5-HT in the fluoxetine group vs. the two other
groups, with no differences between them (Figure 3B).
The fluoxetine challenge reduced extracellular 5-HT to
53% of baseline in controls (maximal effect size: 47%).
Thus, a reduction to 72% of baseline (effect size: 28%) in
the fluoxetine-treated group can be equated to a 40%
fall in the overall sensitivity of DR 5-HT1A autoreceptors.
The administration of WAY-100635 (0.3 mg/kg, s.c.)
reversed the fluoxetine-induced decrease in extracellu-
lar 5-HT in all three groups (significant effect of time,
F9,153 5 25.68, p , .001; non-significant effect of the
group and of time 3 group interaction; fractions 10–19)
(Figure 3A).
To assess whether the prolonged treatment with
WAY-100635 alone could alter the sensitivity of 5-HT1A
autoreceptors, we conducted an additional experiment.
Two groups of rats were treated with vehicle or WAY-
100635 0.3 mg/kg·day, as above (n 5 6 rats/group).
The administration of 10 mg/kg, i.p. fluoxetine re-
duced comparably extracellular 5-HT in both groups
(maximal decrease to 60 6 7% in controls and to 61 6
6% of baseline in WAY 100635-treated rats). Two-way
ANOVA of fractions 1–13 (effect of the fluoxetine chal-
lenge) indicated a significant effect of time (F12,96 5 3.44,
p , .001) but not of the group or the time 3 group inter-
action, indicating the absence of differences between
the two groups. Likewise, the average reduction of ex-
tracellular 5-HT during the period of maximal effect
(fractions 8–13) was 62.6 6 5.6% of baseline in controls
and 68.8 6 5.4% in WAY-100635-treated rats (non-sig-
nificant difference; Student’s t-test). As in previous ex-
periments, the administration of WAY-100635 com-
pletely reversed the fluoxetine-induced reduction of
extracellular 5-HT.
Autoradiographic and In Situ 
Hybridization Experiments
Representative midbrain sections showing the DR la-
beled by [3H]8-OH-DPAT and by the probe comple-
mentary to the mRNA encoding the 5-HT1A receptors
are displayed in Figures 4A and 4B, respectively. The
pretreatment with fluoxetine 3 mg/kg·day alone or in
combination with 0.3 mg/kg·day WAY-100635 did not
significantly alter the labeling of 5-HT1A receptors by
[3H]8-OH-DPAT binding to the DR, area CA1 or den-
tate gyrus (DG) (Figure 4C). Likewise, the treatment
with WAY-100635 alone did not significantly modify
the labeling in any of the brain regions (24.4 6 3.6 and
21.2 6 1.05 in the DR, 44.1 6 1.5 and 43.2 6 0.9 in DG,
31.9 6 1.4 and 30.2 6 1.5 in CA1 for controls and WAY-
100635-reated rats, respectively; data in fmol/mg tis-
sue; n 5 4–5 rats/group).
No significant differences were noted between any
treated group and the respective controls in the density
Figure 4. Effects of the two-week treatment with fluoxetine
3 mg/kg·day alone (FLX 3) or in combination with WAY-
100635 0.3 mg/kg·day (FLX 3 1 WAY 0.3) on the density of
5-HT1A receptors and their mRNA. (A, B) Consecutive coro-
nal sections through the DR of a control rat showing the
autoradiographic labeling of 5-HT1A receptors with [3H]-
8-OH-DPAT (A) and the distribution of 5-HT1A receptor
mRNA (B); bar 5 2mm. (C) Quantitative measurements of
the labeling of 5-HT1A receptors labeled with [3H]-8-OH-
DPAT in the different treatment groups (n 5 6–8 rats/
group). (D) Densitometric measurements of 5-HT1A receptor
mRNA. Film optical density in brain regions devoid of spe-
cific hybridization signal was 0.09 (n 5 5–8 rats/group).
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of the mRNA encoding the 5-HT1A receptor in the DR or
hippocampus (Figure 4D). Also, the treatment with
WAY alone did not induce any change in the density of
the mRNA neither in the DR (0.25 6 0.02 vs. 0.22 6
0.01) nor in the DG (0.44 6 0.01 vs. 0.47 6 0.03), or CA1
(0.27 6 0.01 vs. 0.27 6 0.01) for controls and WAY-
100635-treated rats, respectively (data are optical densi-
ties; n 5 4–5 rats/group).
DISCUSSION
Two findings derive from the present study. First, a
two-week treatment with a low fluoxetine dose desen-
sitized 5-HT1A autoreceptors. Second, the 5-HT1A recep-
tor antagonist WAY-100635 prevented this effect but
did not sensitize nor up-regulated 5-HT1A autoreceptors
when given alone or in combination with fluoxetine.
These in vivo observations are important for the design
of therapeutic strategies based on SSRI 1 5-HT1A antag-
onist combinations. Several 5-HT1A receptor antagonists
and dual action compounds are being developed. The
present data suggest that withdrawal of such com-
pounds would not result in a clinical relapse due to an
exacerbation of the 5-HT1A autoreceptor-based negative
feed-back that offsets the increase in 5-HT produced by
SSRIs in forebrain.
With few exceptions, most studies assessing the ef-
fects of the long-term administration of SSRIs on the 5-HT
system employed relatively large daily doses (e.g.,
10–20 mg/kg·day) that inhibit maximally the 5-HT re-
uptake and markedly increase extracellular 5-HT in
forebrain when given at once (Invernizzi et al. 1994,
1995; Rutter et al. 1994; Arborelius et al. 1996; Gundlah
et al. 1997).
In the present study, we used a fluoxetine dose in-
tended to mimic the early effects of a standard clinical
dose (20 mg/day). In patients treated with this dose,
plasma fluoxetine concentration increased steadily
from 0.08 mM at day 3 to 0.16 mM at day 14 (Pérez et al.
in press). In rats, 5 mg/kg, p.o. fluoxetine yielded a
maximal plasma concentration of 0.15 mM (Caccia et al.
1990). Taking into account the differences between p.o.
and s.c. routes (oral bioavailability in the rat is 38%)
(Caccia et al. 1990), and in absence of more pharmaco-
kinetic data in the literature, we chose 3 mg/kg·day as a
dose that could mimic the effects of fluoxetine in de-
pressed patients. This dose elicits a moderate increase
of extracellular 5-HT in frontal cortex and other fore-
brain areas when given at once (Hervás and Artigas
1998). Yet, due to the greater 5-HT increase in midbrain,
it is sufficient to activate 5-HT1A autoreceptors, as
shown by the fact that WAY-100635 potentiated its ef-
fects on extracellular 5-HT, to a level similar to that elic-
ited by higher (10–20 mg/kg) fluoxetine doses (Malagié
et al. 1995, 1996; Hervás and Artigas 1998).
In keeping with previous observations using a low
fluvoxamine dose (Bel and Artigas 1993, 1996), the
treatment with 3 mg/kg·day fluoxetine for two weeks
significantly increased extracellular 5-HT in frontal cor-
tex (to 275% of controls). The magnitude of the change
was much greater than that produced by a single ad-
ministration of the same dose (compare Figures 1 and
2). Rats treated for two weeks with fluoxetine and
WAY-100635 displayed a similar increase of extracellu-
lar 5-HT (to 245% of controls). This may appear at vari-
ance with the WAY-100635-induced potentiation ob-
served in acute experiments. It is possible that
differences in 5-HT1A receptor desensitization between
the two groups can explain this discrepancy (see below).
The greater baseline extracellular 5-HT in the treated
groups was not observed when 1 mM citalopram was
present in the perfusion fluid. It may be that such dif-
ferences are overcome by the more marked effect of cit-
alopram on extracellular 5-HT (1 mM citalopram in-
creased extracellular 5-HT five-fold in frontal cortex)
(Hervás et al. 2000). Furthermore, it has been shown
that a washout period can abolish the increase in extra-
cellular 5-HT elicited by chronic SSRI treatment (Ar-
borelius et al. 1996). Since citalopram was present in the
perfusion fluid from the beginning of the experiments,
we could not determine which of these factors is ac-
countable.
The systemic administration of the fluoxetine chal-
lenge (10 mg/kg, i.p.) markedly reduced extracellular
5-HT in frontal cortex with citalopram in the perfusion
fluid. This agrees with previous data in the literature
using this and other SSRIs (Rutter and Auerbach 1993;
Auerbach et al. 1995; Romero and Artigas 1997; Hervás
and Artigas 1998). It may appear paradoxical that the
net effect of fluoxetine on extracellular 5-HT (increase
or decrease) depends on the experimental condition
used. This difference is due to the fact that SSRIs and, in
general, 5-HT uptake blockers behave as indirect ago-
nists of raphe 5-HT1A autoreceptors (see Artigas et al.
1996 for review) and reduce 5-HT release.
In normal conditions (i.e., without an SSRI in the per-
fusion fluid), this effect is more than compensated by
the inhibition of 5-HT reuptake in nerve terminals and,
therefore, they increase extracellular 5-HT at moderate
and high doses. However, in conditions of local inhibi-
tion of reuptake in forebrain, the local (in raphe) or sys-
temic administration of selective and non-selective
5-HT reuptake inhibitors results in a reduction of 5-HT
release in forebrain (Adell and Artigas 1991; Rutter and
Auerbach 1993; Auerbach et al. 1995; Romero and Arti-
gas 1997). This effect involves the activation of raphe
5-HT1A receptors, as it is antagonized by WAY-100635
and non-selective 5-HT1A antagonists (Hjorth and Auer-
bach 1994b; Romero et al. 1994; Auerbach et al. 1995;
Romero and Artigas 1997; Hervás and Artigas 1998).
Therefore, the reduction in extracellular 5-HT in frontal
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cortex during local blockade of the 5-HT uptake can be
used as a functional index of the sensitivity of raphe
5-HT1A autoreceptors. The use of SSRIs to probe the
sensitivity of 5-HT1A autoreceptors is preferable to that
of direct 5-HT1A agonists (e.g., 8-OH-DPAT) since these
may also decrease extracellular 5-HT in frontal cortex
through the activation of postsynaptic 5-HT1A receptors
(Casanovas et al. 1999b).
The decrease in 5-HT produced by the fluoxetine
challenge in rats pretreated with fluoxetine 3 mg/
kg?day was significantly less marked than in control
rats. The in vivo release of 5-HT in frontal cortex de-
pends on the activity of DR neurones (McQuade and
Sharp 1997). Thus, the present results suggest that the
fluoxetine pretreatment desensitized 5-HT1A autorecep-
tors in the DR. The magnitude of the change may ap-
pear moderate, but is similar to that produced by a
maximal daily dose of a selective 5-HT1A receptor ago-
nist given for the same time period (Casanovas et al.
1999a). The fact that the desensitization is not complete
(i.e., the fluoxetine challenge could still significantly re-
duce extracellular 5-HT in fluoxetine-pretreated rats)
agrees with other studies showing that 5-HT1A autore-
ceptor antagonists can increase the activity of DR 5-HT
cells and augment the effect of the chronic treatment
with a high citalopram dose (20 mg/kg?day) on cortical
extracellular 5-HT (Arborelius et al. 1996; Gundlah et al.
1997).
The presence of WAY-100635 in the minipumps pre-
vented the desensitization of 5-HT1A receptors pro-
duced by fluoxetine pretreatment, as shown by the
identical reduction of extracellular 5-HT in controls and
in the group treated with the combination. Likewise,
the pretreatment with the same daily dose of WAY-
100635 alone did not alter the ability of the fluoxetine
challenge to reduce extracellular 5-HT compared with
the respective controls. Both observations suggest that
the continuous blockade of 5-HT1A receptors by WAY-
100635, alone or with fluoxetine, did not result in recep-
tor sensitization. The differences in sensitivity of
5-HT1A receptors between the fluoxetine and fluoxetine
plus WAY-100635 groups suggest that the increase in
extracellular 5-HT observed at the 14th day of treat-
ment (no washout) may have a different origin. Hence,
the 5-HT elevation can be tentatively ascribed to 5-HT1A
autoreceptor desensitization (fluoxetine alone) and to
the presence of the 5-HT1A antagonist (fluoxetine plus
WAY-100635).
The change in 5-HT1A autoreceptor sensitivity in the
fluoxetine-pretreated group was not accompanied by a
decrease in the labeling of 5-HT1A receptors or their en-
coding mRNA in the DR. Also, postsynaptic 5-HT1A re-
ceptors in hippocampus were unaffected. It should be
emphasized that both observations (change in receptor
sensitivity and unchanged density) have been obtained
in the same animals. Previous work with SSRIs and se-
lective 5-HT1A agonists is inconclusive in regards to the
ability of these agents to down-regulate the density of
raphe 5-HT1A autoreceptors after chronic (2–3 weeks)
treatments (Welner et al. 1989; Hensler et al. 1991;
Fanelli and McMonagle-Strucko 1992; Casanovas et al.
1999a; Le Poul et al. 1999), whereas there is convincing
evidence on their ability to induce a functional desensi-
tization (Blier and de Montigny 1987, 1994; Hensler et
al. 1991; Invernizzi et al. 1994; Casanovas et al. 1999a;
see however Sharp et al. 1993).
Overall, our observations accord with the un-
changed receptor density observed in some of the
above rat studies. They are also in agreement with a re-
cent report indicating that prolonged treatment with
SSRIs did not change the labeling of pre- and post-
synaptic 5-HT1A receptors in depressed patients, as
assessed by positron emission tomography with
[11CO]WAY-100635 (Sargent et al. 2000). On account of
the present observations, the unchanged receptor den-
sity in the latter study does not preclude the existence
of a functional receptor desensitization. The mismatch
between receptor desensitization and unchanged recep-
tor density may be tentatively explained by a reduction
in midbrain Gi and Go proteins that would diminish the
efficacy of the coupling to the effector system (Li et al.
1996). Also, it is unclear whether receptor autoradiogra-
phy can visualize internalized receptors in addition to
those on the membrane.
In keeping with the above functional studies, the
prolonged treatment with WAY-100635 alone or in
combination with fluoxetine did not up-regulate the
density of 5-HT1A receptors and its encoding mRNA.
These in vivo observations may appear at variance with
the widely held concept of receptor sensitization/up-
regulation by antagonists. To our knowledge, this is the
first study assessing the in vivo effects of the prolonged
blockade of 5-HT1A receptors on their sensitivity/label-
ing in rat brain, and therefore the present conclusions
must await further confirmation. Likewise, few in vitro
data are also available. Exposure to WAY-100635 of a
stable cell line transfected with human 5-HT1A receptors
resulted in a paradoxical receptor down-regulation
(Smith et al. 1998) despite the fact that WAY-100635 has
no intrinsic activity (Newman-Tancredi et al. 1998).
This observation, although puzzling, is indicative that
WAY-100635 does not up-regulate or sensitize 5-HT1A
autoreceptors in vitro. Yet, given the different experi-
mental conditions between both studies, any similarity
may be coincidental.
In summary, the present results show that a two
week treatment with a low fluoxetine dose markedly
increases extracellular 5-HT in frontal cortex and desen-
sitizes 5-HT1A autoreceptors in the DR. This change oc-
curs without a parallel modification of the 5-HT1A re-
ceptor protein/mRNA. WAY-100635 enhances the
effect of fluoxetine after single treatment and prevents
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the desensitization induced by chronic fluoxetine but
does not sensitize or up-regulate 5-HT1A autoreceptors.
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